Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases
AssigneeImmunic AG
InventorsManfred GROPPEL, Daniel VITT, Hella KOHLHOF, Andreas MÜHLER
Life of this patent
Estimating the term…
Abstract
The present invention refers to a 2-({3-fluoro-3′-methoxy-[1,1′-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid) according to formula (I) and a novel dosage regimen as well as their uses in the treatment of chronic inflammatory and/or autoimmune diseases. The said compound of formula (I) inhibits dihydroorotate dehydrogenase (DHODH), and is known for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).
Claims9
1-11. (canceled)
A method of treating a chronic inflammatory and/or autoimmune disease in a subject in need thereof, the method comprising:
- a. administering to the subject at least one compound each day for 5 to 10 days at an initial daily dose of about 14 μmol to about 130 μmol per day;
- and thereafter
- b. administering to the subject the at least one compound at a subsequent daily dose,
- wherein the subsequent daily dose is 1.5 to 8-fold higher than the initial daily dose, and
- wherein the at least one compound is 2-({3-fluoro-3′-methoxy-[1,1′-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid) according to formula (I) or a pharmaceutically-acceptable salt or solvate thereof.
Dependencies are inferred from the claim text.